Biological therapy for ulcerative colitis: What is after anti-TNF

Gionata Fiorino, Monica Cesarini, Silvio Danese

Research output: Contribution to journalArticle

Abstract

Ulcerative Colitis (UC) is an idiopathic chronic inflammation. Its etiology is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms are thought to trigger the gut inflammation, leading to the activation of the intestinal immune response. Immune and non-immune cells create a cross talk via the secretion of soluble mediators and expression of cell adhesion molecules, resulting in further cell activation. Mediators such as cytokines and chemokines play a key role in cell recruitment and polarization, intercellular signal amplification or activation and differentiation. Lack of balance between pro-inflammatory and anti-inflammatory cytokines is crucial in the pathogenesis of IBD. Conventional therapy of UC quite commonly fails to avoid complications or colectomy and the therapeutic armamentarium remains still limited. New therapeutic options, such as, biological therapy, gene therapy, hematopoietic stem cell transplantation, and leucoapheresis, have been investigated recently. Biological therapy is focused on different targets involved in the inflammatory process. Several new biological drugs have been introduced in the last decade or are under investigation for the treatment of IBD. They include anti TNF-α agents, anti adhesion molecules, anti IL-12/23, anti IL-6R and more. We review the recent advances in biological therapy for UC treatment beyond the anti-TNFs.

Original languageEnglish
Pages (from-to)1433-1439
Number of pages7
JournalCurrent Drug Targets
Volume12
Issue number10
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Biological Therapy
Ulcerative Colitis
Chemical activation
Cytokines
Gene therapy
Cell Adhesion Molecules
Interleukin-12
Stem cells
Chemokines
Microorganisms
Amplification
Inflammation
Interleukin-23
Anti-Inflammatory Agents
Therapeutics
Adhesion
Polarization
Colectomy
Hematopoietic Stem Cell Transplantation
Molecules

Keywords

  • Anti adhesion-molecules
  • Anti TNF-α
  • Anti-CD25
  • Biologics
  • Cytokines
  • Growth factors
  • PPAR-γ
  • Ulcerative colitis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Biological therapy for ulcerative colitis : What is after anti-TNF. / Fiorino, Gionata; Cesarini, Monica; Danese, Silvio.

In: Current Drug Targets, Vol. 12, No. 10, 09.2011, p. 1433-1439.

Research output: Contribution to journalArticle

@article{cd7f1f93f01a4ac89d40de277a9880ab,
title = "Biological therapy for ulcerative colitis: What is after anti-TNF",
abstract = "Ulcerative Colitis (UC) is an idiopathic chronic inflammation. Its etiology is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms are thought to trigger the gut inflammation, leading to the activation of the intestinal immune response. Immune and non-immune cells create a cross talk via the secretion of soluble mediators and expression of cell adhesion molecules, resulting in further cell activation. Mediators such as cytokines and chemokines play a key role in cell recruitment and polarization, intercellular signal amplification or activation and differentiation. Lack of balance between pro-inflammatory and anti-inflammatory cytokines is crucial in the pathogenesis of IBD. Conventional therapy of UC quite commonly fails to avoid complications or colectomy and the therapeutic armamentarium remains still limited. New therapeutic options, such as, biological therapy, gene therapy, hematopoietic stem cell transplantation, and leucoapheresis, have been investigated recently. Biological therapy is focused on different targets involved in the inflammatory process. Several new biological drugs have been introduced in the last decade or are under investigation for the treatment of IBD. They include anti TNF-α agents, anti adhesion molecules, anti IL-12/23, anti IL-6R and more. We review the recent advances in biological therapy for UC treatment beyond the anti-TNFs.",
keywords = "Anti adhesion-molecules, Anti TNF-α, Anti-CD25, Biologics, Cytokines, Growth factors, PPAR-γ, Ulcerative colitis",
author = "Gionata Fiorino and Monica Cesarini and Silvio Danese",
year = "2011",
month = "9",
doi = "10.2174/138945011796818225",
language = "English",
volume = "12",
pages = "1433--1439",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Biological therapy for ulcerative colitis

T2 - What is after anti-TNF

AU - Fiorino, Gionata

AU - Cesarini, Monica

AU - Danese, Silvio

PY - 2011/9

Y1 - 2011/9

N2 - Ulcerative Colitis (UC) is an idiopathic chronic inflammation. Its etiology is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms are thought to trigger the gut inflammation, leading to the activation of the intestinal immune response. Immune and non-immune cells create a cross talk via the secretion of soluble mediators and expression of cell adhesion molecules, resulting in further cell activation. Mediators such as cytokines and chemokines play a key role in cell recruitment and polarization, intercellular signal amplification or activation and differentiation. Lack of balance between pro-inflammatory and anti-inflammatory cytokines is crucial in the pathogenesis of IBD. Conventional therapy of UC quite commonly fails to avoid complications or colectomy and the therapeutic armamentarium remains still limited. New therapeutic options, such as, biological therapy, gene therapy, hematopoietic stem cell transplantation, and leucoapheresis, have been investigated recently. Biological therapy is focused on different targets involved in the inflammatory process. Several new biological drugs have been introduced in the last decade or are under investigation for the treatment of IBD. They include anti TNF-α agents, anti adhesion molecules, anti IL-12/23, anti IL-6R and more. We review the recent advances in biological therapy for UC treatment beyond the anti-TNFs.

AB - Ulcerative Colitis (UC) is an idiopathic chronic inflammation. Its etiology is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms are thought to trigger the gut inflammation, leading to the activation of the intestinal immune response. Immune and non-immune cells create a cross talk via the secretion of soluble mediators and expression of cell adhesion molecules, resulting in further cell activation. Mediators such as cytokines and chemokines play a key role in cell recruitment and polarization, intercellular signal amplification or activation and differentiation. Lack of balance between pro-inflammatory and anti-inflammatory cytokines is crucial in the pathogenesis of IBD. Conventional therapy of UC quite commonly fails to avoid complications or colectomy and the therapeutic armamentarium remains still limited. New therapeutic options, such as, biological therapy, gene therapy, hematopoietic stem cell transplantation, and leucoapheresis, have been investigated recently. Biological therapy is focused on different targets involved in the inflammatory process. Several new biological drugs have been introduced in the last decade or are under investigation for the treatment of IBD. They include anti TNF-α agents, anti adhesion molecules, anti IL-12/23, anti IL-6R and more. We review the recent advances in biological therapy for UC treatment beyond the anti-TNFs.

KW - Anti adhesion-molecules

KW - Anti TNF-α

KW - Anti-CD25

KW - Biologics

KW - Cytokines

KW - Growth factors

KW - PPAR-γ

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=80051690479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051690479&partnerID=8YFLogxK

U2 - 10.2174/138945011796818225

DO - 10.2174/138945011796818225

M3 - Article

C2 - 21466492

AN - SCOPUS:80051690479

VL - 12

SP - 1433

EP - 1439

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 10

ER -